Manjula Reddy Pallerla, Bhairaiah Mara, Ramesh babu Konda, Ataharoddin Khaja, Cyclic Peptides: Prominent Next Generation Targeted Therapies, Journal of Peptides, Volume 1, Issue 2, 2026, Pages 1-13, ISSN Coming Soon, https://doi.org/.
(https://oap-cancer.org/peptides/article/cyclic-peptides-prominent-next-generation-targeted-therapies-2384)
Abstract: Cyclic peptides are expected to play a significant role in the future of drug discovery and development. Their unique properties, such as enhanced target affinity, metabolic stability, and favorable pharmokinetic profiles, make them promising candidates for addressing complex therapeutic targets. Innovations in design and synthetic techniques, including phage display and genetic code expansion with noncanonical amino acids, are enabling the development of diverse cyclic peptide libraries. These advancements are expected to bridge the gap between traditional small molecules and biologics, offering significant promise in the treatment of complex diseases. The therapeutic potential of cyclic peptides is broad, with applications in various pharmacological activities, including antibiotics, antifungals, anticancer, and immunosuppressants. The number of cyclic peptide drugs under research has reached hundreds, some have entered the late clinical stage. With ongoing research, more cyclic peptide drugs are expected to be approved and enter the market in the future. Cyclic peptides are also valuable research tools, suitable for probes that selectively modulate target proteins or high affinity ligands for biomolecular imaging. The development of selection strategies and various cyclization strategies, non-natural amino acids, and functional building blocks further enhance their functionality and utility in drug development. In summary, Cyclic peptides are poised to be a valuable class of molecules in the future, with ongoing research and development efforts aimed at optimizing their properties and expanding their therapeutic applications. .
Keywords: Macrocycles; Drug discovery; Cyclization strategy; Drug development; Therapeutic peptides; Screening technology